Drug Trial Radar · NCT06500234
Nutrition Impact on Immunotherapy of Cancer
Last checked: Nov 20, 2026Latest source record: Jul 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Jun 1, 2024
Primary completion
May 31, 2025
Study completion May 31, 2027
Sponsor
- Lead sponsor
- Qingdao Central HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jul 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study investigates nutritional status and outcomes of immuntherapy in cancer patients.
Conditions
- Nutrition Disorders
- Immunotherapy
- Cancer
- Survival, Prosthesis
Interventions
Megestrol Acetate and olanzapineDrug
megestrol acetate, 160 mg, oral everyday; olanzapine 2.5 mg, oral everyday
Starch powder 50 mgDrug
Starch powder 50 mg, oral, everyday
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Qingdao Central Hospital
Qingdao, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.